ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2733

Spontaneous Osteoarthritis In Mice By Genetic Deletion Of Nfatc1 and Nfatc2

Susan Y. Ritter1, Matthew B. Greenblatt2, Kelly Tsang1, Dorothy Z. Hu3, John Wright4 and Antonios O. Aliprantis1, 1Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Pathology, Brigham and Women's Hospital, Boston, MA, 3Endocrine Unit, Massachusetts General Hospital, Boston, MA, 4Orthopedic Surgery, Brigham and Women's Hospital, Boston, MA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Mouse model, osteoarthritis and transcription factor

  • Tweet
  • Email
  • Print
Session Information

Title: Biology and Pathology of Bone and Joint II: Osteoclast Biology and Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Osteoarthritis (OA) was once viewed as a mechanical disease of “wear and tear”, but recent advances suggest that OA results from active dysregulation of chondrocyte biology leading to catabolism of the cartilage matrix. Little is understood regarding the transcription factors that regulate this catabolic program and ultimately the development of OA. Nuclear factor of activated T cells (NFATs) are a family of transcription factors with broad roles in vertebrate physiology including immune responses and tissue development. Since NFAT family members often display redundant functions and NFATc2-deficient mice were previously shown to develop OA at older ages, we tested the role of NFATc1 in OA.

Methods:

Mice bearing two copies of a floxed allele of Nfatc1 (Nfatc1fl/fl) were crossed  to Col2-cre mice to delete the gene in cartilage (Nfatc1col2 mice). Nfatc1col2 mice were analyzed in the destabilization of the medial meniscus (DMM) model of OA. The Nfatc1col2 strain was bred onto the NFATc2-deficient background to generate Nfatc1col2Nfatc2-/- mice. These mice were analyzed by microCT, immunohistochemistry and quantitative real-time PCR (qPCR) of mRNA isolated from dissected cartilage tissue. mRNA purified from human cartilage tissue from joint replacement surgery was also interrogated for NFATC1 and NFATC2 expression by qPCR.

Results:

NFATc1col2 mice were not more susceptible to OA in the DMM model than littermate controls, suggesting that in mice, NFATc1 deficiency is not sufficient to accelerate OA. In contrast, cartilage-specific ablation of Nfatc1 in Nfatc2-/- mice led to a spontaneous, early onset, aggressive OA. The arthritis affects multiple joints including the knees, elbows and tarsal-metatarsal joints and is associated with subluxations. Histologically, joints from Nfatc1col2Nfatc2-/- mice showed loss of proteoglycans, increases in collagen and aggrecan degradation products and eventual progression to cartilage effacement. MicroCT demonstrated increased osteophyte formation and changes to the subchondral bone in Nfatc1col2Nfatc2-/- mice. Compared with littermate controls, cartilage dissected from the knee joints of Nfatc1col2Nfatc2-/- mice showed increased expression of: Mmp13, Adamts5, Col2a1 and Htra1. Lastly, NFATC1 expression is downregulated in paired lesional versus macroscopically normal cartilage samples from OA patients (1.63 vs. 2.72, p=0.0065 by paired t-test). No significant change was observed in NFATC2 expression (2.44 vs. 2.06, p=0.214).

Conclusion:

NFATs are suppressors of OA and regulating NFATs or their transcriptional targets in chondrocytes may lead to novel disease modifying OA therapies. The Nfatc1col2Nfatc2-/- mice have a highly penetrant, early onset and severe OA phenotype, which could be an attractive platform for the preclinical development of treatments to alter the course of this disease.


Disclosure:

S. Y. Ritter,
None;

M. B. Greenblatt,
None;

K. Tsang,
None;

D. Z. Hu,
None;

J. Wright,
None;

A. O. Aliprantis,

Nutech Medical,

5.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/spontaneous-osteoarthritis-in-mice-by-genetic-deletion-of-nfatc1-and-nfatc2/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology